HER2 Testing Market Size & Share, by Technique (Immunohistochemistry (IHC) Test, Fluorescence in Situ Hybridization, Chromogenic in Situ Hybridization, Silver-Enhanced in Situ Hybridization); Cancer Type (Breast Cancer, Gastric Cancer, Bladder Cancer, Ovarian Cancer); End Users (Hospital, Diagnostic Centers, Specialty Clinics) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

Growth Drivers

• Technology developments in the HER 2 testing to support market expansion- Imaging technology developments enhance screening and early detection. Modern testing technologies are available for use in clinical practices with HER2 testing, which targets trastuzumab treatment for patients with breast cancer. Trastuzumab treatment is very successful for 20–30% of patients with breast tumors that overexpress the HER2 gene, according to HER2 testing that has been developed. One effective test that has been utilized in clinical practice to focus on cancer treatment is HER2 testing. Patients with metastatic HER2-positive breast cancer are seeing higher odds of survival after using anti-HER2 therapy than those with HER2-negative disease. During the patient's first line of treatment, the double HER2 blockage using a combination of trastuzumab and pertuzumab along with a taxane achieved an exceptional survival rate. The HER2 testing market is growing because of all the technological developments in HER2 testing.
• Rising Breast Cancer Prevalence- The most prevalent malignancy in women to be diagnosed is breast cancer. Breast cancer is primarily caused by menopause, early childbirth, and later marriage ages. The late age of marriage and delivery, increased exposure to non-estrogen-producing mutagens, and the genotoxicity of estrogen are the causes of the lack of breast tissue differentiation. After menopause, there is a longer period of exposure to estrogen. Breast cancer risk is increased by specific hereditary high penetrance gene mutations. Women discovered that various abnormalities in these main genes, including BRCA1, BRCA2, and PALB-2, have been leading to risk reduction techniques, such as surgically removing both breasts.
• Increasing the Gastric Cancer Prevalence will accelerate HER2 testing market expansion- Helicobacter pylori infection and autoimmune gastritis, which arises when the body's immune system targets the stomach lining, are the main causes of gastric cancer. Radiation, obesity, and tobacco usage are further reasons which cause. Globally, males have a 1.87 percent chance of developing stomach cancer from birth to age 74, while females have a 0.79 percent chance. The most frequent cause of cancer-related death was gastric cancer. Male gastric cancer is the most lethal type of the disease, with 783,000 deaths annually.

Challenges

• Exorbitant price for HER 2 testing- Due to the high expense of the HER 2 test, neither the middle class nor the lower class can afford it. Trastuzumab, an advanced HER 2 test, is quite expensive. For each patient treated in an adjuvant or metastatic breast cancer context, trastuzumab costs USD 49,915 and USD 28,350, respectively. Globally, the high cost of trastuzumab therapies places a heavy financial strain on local health budgets.
• Throughout the projection period, the expansion of the worldwide HER2 testing market could be restricted by a lack of skilled specialists who are unaware of the best ways to treat this illness.
• Several pharmaceuticals' expiring patents are impeding the growth of the HER2 testing market.  The market's growth is being hampered by the main brands' patent expirations, especially Perjeta, Herceptin, and Kadcyla, which accounted for the majority of sales.